Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Eradication of melanomas by targeted elimination of a minor subset of tumor cells.

Schmidt P, Kopecky C, Hombach A, Zigrino P, Mauch C, Abken H.

Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2474-9. doi: 10.1073/pnas.1009069108.

2.

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M.

Cancer Cell. 2010 Dec 14;18(6):683-95. doi: 10.1016/j.ccr.2010.11.023.

3.

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.

Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS.

Nature. 2010 Dec 16;468(7326):973-7. doi: 10.1038/nature09626.

4.

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA.

Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627.

5.

Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized.

Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM, Morrison SJ.

Cancer Cell. 2010 Nov 16;18(5):510-23. doi: 10.1016/j.ccr.2010.10.012.

6.

Inhibition of mutated, activated BRAF in metastatic melanoma.

Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB.

N Engl J Med. 2010 Aug 26;363(9):809-19. doi: 10.1056/NEJMoa1002011.

7.

Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271.

Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, Butler PD, Yang GP, Joshua B, Kaplan MJ, Longaker MT, Weissman IL.

Nature. 2010 Jul 1;466(7302):133-7. doi: 10.1038/nature09161. Erratum in: Nature. 2011 Feb 17;470(7334):424.

8.

A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.

Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T, Herlyn M.

Cell. 2010 May 14;141(4):583-94. doi: 10.1016/j.cell.2010.04.020.

9.

Mutation-driven drug development in melanoma.

Flaherty KT, Hodi FS, Bastian BC.

Curr Opin Oncol. 2010 May;22(3):178-83. Review.

10.

Heterogeneity in cancer: cancer stem cells versus clonal evolution.

Shackleton M, Quintana E, Fearon ER, Morrison SJ.

Cell. 2009 Sep 4;138(5):822-9. doi: 10.1016/j.cell.2009.08.017.

11.

Looking ahead in cancer stem cell research.

Dick JE.

Nat Biotechnol. 2009 Jan;27(1):44-6. doi: 10.1038/nbt0109-44. No abstract available.

PMID:
19131997
12.

Efficient tumour formation by single human melanoma cells.

Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ.

Nature. 2008 Dec 4;456(7222):593-8. doi: 10.1038/nature07567.

13.

Identification of cells initiating human melanomas.

Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS, Sayegh MH, Frank MH.

Nature. 2008 Jan 17;451(7176):345-9. doi: 10.1038/nature06489.

14.

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.

Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, Hwu P.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15.

15.

Melanoma.

Miller AJ, Mihm MC Jr.

N Engl J Med. 2006 Jul 6;355(1):51-65. Review. No abstract available.

PMID:
16822996
16.

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.

Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, Gratama JW, Stoter G, Oosterwijk E.

J Clin Oncol. 2006 May 1;24(13):e20-2. No abstract available.

PMID:
16648493
17.

A tumorigenic subpopulation with stem cell properties in melanomas.

Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M.

Cancer Res. 2005 Oct 15;65(20):9328-37.

19.

CD20: a regulator of cell-cycle progression of B lymphocytes.

Tedder TF, Engel P.

Immunol Today. 1994 Sep;15(9):450-4. Review.

PMID:
7524522
Items per page

Supplemental Content

Support Center